Published in
Springer, Breast Cancer Research and Treatment, 3(184), p. 743-753, 2020
DOI: 10.1007/s10549-020-05891-0
Links
Tools
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
Journal article published in 2020 by
Ji-Yeon Kim,
Kyunghee Park,
Seock-Ah Im,
Kyung Hae Jung,
Joohyuk Sohn 
,
Keun Seok Lee,
Jee Hyun Kim,
Yaewon Yang,
Yeon Hee Park
,
Keun Seok Lee,
Jee Hyun Kim,
Yaewon Yang,
Yeon Hee Park
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 